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Abstract
Rationale and aim To compare clinical features and management of paediatric
community-acquired pneumonia (PCAP) following the publication of UK pneumonia
guidelines in 2002 with data from a similar survey at the same hospitals in 2001–2002
(pre-guidelines).
Methods Aprospective survey of 11 hospitals in Northern England was undertaken during
2008–2009. Clinical and laboratory data were recorded on children aged ≤16 years who
presented with clinical and radiological features of pneumonia.
Results 542 children were included. There was a reduction in all investigations performed
(P < 0.001) except C-reactive protein (P = 0.448) between surveys. These included full
blood count (76% to 61%); blood culture (70% to 53%) and testing of respiratory secretions
for viruses (24% to 12%) and bacteria (18% to 8%). Compared to pre-guidelines, there
was a reduction in the use of intravenous antibiotics as a proportion of the total prescribed
from 47% to 36% (P < 0.001) and a change in the route of antibiotic administration with
increasing preference for oral alone (16% pre-compared to 50% post-guidelines,
P < 0.001).
Conclusion Apart from the acute phase reactants that should not be measured routinely,
these changes are in line with the guideline recommendations. Improvements in antibiotic
use are possible and have implications for future antimicrobial stewardship programmes.
Further work using cost-effectiveness analysis may also demonstrate a financial benefit to
health services from adoption of guidelines.
Introduction
Paediatric community-acquired pneumonia (PCAP) is a frequent
cause of admission to hospital [1,2]. Clinical features of pneumo-
nia are often non-specific in young children [3,4]. Management
decisions are generally based on a combination of clinical signs,
symptoms and radiological changes [3,5]. National UK clinical
guidelines for management of PCAP were published in 2002 [6]
and updated in 2011 [1] by the British Thoracic Society (BTS).
They synthesized evidence and expert opinion to produce best
practice national standards, which included statements on investi-
gations and antibiotics use (Table 1) [6].
Antibiotic stewardship programmes and management guide-
lines have been shown to improve the selection of appropriate
investigations and antibiotics for management of infections in
children [7–11]. These measures allow better use of health
resources and reduction of antibiotic drug resistance which are
becoming global challenges [12–17].
In theUK, the 7-valent pneumococcal conjugate vaccine (PCV7)
was introduced routinely from September 2006. It was associated
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with a reduction in the incidence of PCAP and rate of hospitaliza-
tion [18].We therefore aimed to explore changes in themanagement
of children with pneumonia seen in hospital in the context of the
national guidelines. Presentation and management outcomes of
pneumonia in children in the present surveywere compared to those
previously described in a similar survey conducted in the same
region in 2001–2002 [3], prior to the publication of the BTS
management recommendations for PCAP in 2002 [6]. Such find-
ings are important for doctors involved in the management of this
infection and for experts updating these guidelines.
Methods
Participants
A prospective survey of children aged ≤16 years who presented
with clinical and radiological features of pneumonia at 11 hospi-
tals (sites) was conducted in Northern England (excluding
Cumbria) fromAugust 2008 to July 2009 ‘post-guidelines’. Pneu-
monia was defined as any child with signs or symptoms suggestive
of lower respiratory tract infection including any of fever,
tachypnoea (defined age-specific respiratory rates), dyspnoea,
cough, respiratory distress, chest wall retractions and auscultatory
findings such as crackles, bronchial breathing or reduced breath
sounds together with chest radiographic findings consistent with
pneumonia as determined initially by the local paediatrician.
Exclusions included being resident outside the geographical study
area; clinical bronchiolitis; hospital admission within 3 weeks of
pneumonia admission; or normal chest radiograph. Disease sever-
ity was classified according to the BTS criteria [6]. Chest radio-
graphic changes from the local radiologists’ reports were classified
into patchy, lobar or perihilar consolidations according to the
World Health Organization criteria [19]. ‘Non-end-point changes’
such as increased bronchovascular markings, peribronchial thick-
ening, bronchial wall thickening or peribronchial cuffing were
grouped together in an additional category ‘other infiltrates/
abnormalities’. Exclusions included being resident outside the
geographical study area; clinical bronchiolitis; hospital admission
within 3 weeks of pneumonia admission; or normal chest radio-
graph. This cohort was included in a region-wide survey investi-
gating the impact of PCV7 on the disease incidence and rates of
hospitalization of pneumonia confirmed on chest radiograph [20].
Results were compared with those from an identically
performed survey, using the same recruitment methods and
diagnostic criteria in 2001–2002 ‘pre-guidelines’ [3]. Hospital
reconfigurations reduced the number of units admitting children
from 13 to 11 during the pre- and post-guidelines surveys, respec-
tively. The catchment population and referral pathways from
primary care or accident and emergency departments to paediatric
services remained the same. Ethical approval was obtained from
the Newcastle and North Tyneside Research Ethics Committee.
Caldicott approvals regarding data protection and information
governance were granted from all collaborating sites.
Data collection and case ascertainment
The study team carried out multiple visits to collaborating sites in
order to explain and ascertain the adherence to the enrolment
criteria through a locally identified junior and consultant paedia-
trician at each site. These visits also included supporting the
Caldicott procedures, cross-checking and safe handling of data and
presenting collected results. A family doctor/general practitioner
or medical staff at the accident and emergency departments saw
children before referral for further assessment by the paediatric
team. Children were managed entirely by their local paediatric
team. Data were recorded on standard form and validated by
reviewing ward admission diaries for children admitted with res-
piratory symptoms (eight sites), or by obtaining hospital coding
data on pneumonia where admissions are carried out electronically
(three sites). Hard copy case notes and electronic records were
reviewed to ascertain the data and resolve any missing or incon-
sistent data. Duplicates or those who did not fulfil the enrolment
criteria were removed after the completion of validation process.
Statistical analysis
Descriptive analysis was performed using Epi InfoTM 7 (Centers
for Disease Control and Prevention, Atlanta, GA, USA). Fisher’s
exact test with odds ratios (ORs) and 95% confidence intervals
(CIs) was used to compare categorical variables between groups
and with those from the pre-guidelines survey [3]. Continuous
variables are presented as mean ±standard deviation (SD). Inci-
dence rates per 10 000 children were established for overall rates
of pneumonia, hospitalization, disease severity and radiological
findings and compared between the pre- and post-guidelines
surveys using the population estimates for the North East Strategic
HealthAuthority area from the UK Office of National Statistics for
2009 [21]. There were 458 500 children aged under 16 years. CIs
Table 1 Selected standards from 2002 British Thoracic Society management guidelines of PCAP [6]
• Blood cultures should be performed in all children suspected of having bacterial pneumonia.
• Nasopharyngeal aspirates from all children under the age of 18 months should be sent for viral antigen detection with or without viral culture.
• Acute phase reactants should not be measured routinely.
• Amoxicillin is first choice for oral antibiotic therapy in children aged <5 years and macrolide antibiotics may be used as first line empirical
treatment in children aged ≥5 years.
• Antibiotics administered orally are safe and effective for children presenting with CAP.
• Intravenous antibiotics should be used in the treatment of pneumonia in children when the child is unable to absorb oral antibiotics (for
example, because of vomiting) or presents with severe signs and symptoms.
• Appropriate intravenous antibiotics for severe pneumonia include Co-amoxiclav, Cefuroxime, and Cefotaxime.
• If clinical or microbiological data suggest that Streptococcus pneumoniae is the causative organism, Amoxicillin, Ampicillin or Penicillin alone
may be used.
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of incidence rates were calculated assuming a Poisson distribution
and using the EpiTools package in R statistical software version
2.15.1 (The R Foundation for Statistical Computing, Vienna,
Austria). SPR provided guidance and supervision on data analysis.
Results
A total of 542 were eligible for inclusion (58% males; 74% < 5
years old). Overall, 84% children were admitted (89% pre-
guidelines). None of those who were discharged home after initial
assessment returned to hospital within 3 weeks with clinical fea-
tures suggestive of lower respiratory tract infection. Ten children
required admission to the intensive care for assisted ventilation;
eight were aged <5 years. An underlying co-morbidity was present
in 15% and asthma in 7%. No children died during either survey
periods. The epidemiological outcomes for this cohort are
described in a separate publication [20]. The overall reduction in
annual incidence of pneumonia per 10 000 children between 2001
and 2009 was 17.7% (95% CI 8 to 26); a similar reduction was
observed in annual hospitalization rate 18.5% (95% CI 8 to 28)
[20]. Table 2 compares data between the pre- and post-guidelines
surveys on clinical and radiological features.
Presentation
Among those with pleural effusion, reported lobar changes were
present in 77% post-guidelines compared to 42% pre-guidelines
(OR = 0.2; 95% CI 0.09 to 0.48; P = 0.0002). Pyrexia (triage tem-
perature >38°C) was recorded in 47.4% (333 out of the 702)
pre-guidelines and 50% (266 out of the 531) post-guidelines
(P = 0.358). Rates of admission oxygen saturation <93% were
similar between the pre- (31%, 213 out of the 689) and
post-guidelines surveys (27.4%, 145 out of the 529) (P = 0.204).
Hospitalization was associated with disease severity (P < 0.001),
but not with pyrexia or chest radiographic changes.
Investigations
There was an association between the collection of blood samples
for investigation(s) and use of intravenous (IV) antibiotics pre-
guidelines (P < 0.001), but not post-guideline. There was a reduc-
tion in the number of investigations performed (P < 0.001) except
C-reactive protein (CRP) (P = 0.448) between pre- and post-
guidelines. Full blood count (FBC) decreased from 76% to 61%;
blood culture from 70% to 53%; testing respiratory secretions for
viruses from 24% to 12% and bacteria from 18% to 8%. The yield
of blood culture was the same in both surveys (4% and 4.9%).
Collection of blood culture post-guidelines was not correlated to
disease severity (P = 0.085). Post-guidelines, viral polymerase
chain reaction assays (immunofluorescence test in pre-guidelines)
were performed on respiratory secretions from 66 children with 26
(39%) positive. Obtaining a viral respiratory screen was age-
dependent and more frequently performed in those aged <2 (22%)
than ≥2 years, but less often when compared with pre-guidelines
(34%) (OR = 0.5; 95% CI 0.33 to 0.75; P = 0.001).
CRP was obtained in 322 (59%); of which, 27% were
>100 mg L−1; 9% of infants, 58% of under 5 years old and 42% in
the above five. Pleural effusion was associated with higher CRP
greater than 100 mg L−1 (P < 0.001). Lobar and patchy changes
were associated with a CRP more than 150 mg L−1 (P < 0.05).
Mean values of CRP, total white cell count and neutrophils were
higher with lobar changes (P < 0.001).
Management
Between the pre- and post-guidelines, IV antibiotics as a propor-
tion of the total prescribed antibiotics decreased from 47% (501
out of the 1065) to 36% (318 out of the 891) (OR = 1.6; 95% CI
1.33 to 1.93; P < 0.001), and oral antibiotics alone increased from
16% to 50% (OR = 4.4; 95% CI 3.37 to 5.71; P < 0.001). There
was also a reduction in the use of IV route only from 8% to 5%
(OR = 1.8; 95% CI 1.08 to 2.86; P = 0.025) and the use of both
oral and IV routes (P < 0.001) between the pre- and post-
guidelines, respectively. Post-guidelines, Amoxicillin prescription
both orally and intravenously increased (P < 0.001) with a
decrease in IV cephalosporins (Cefuroxime and Cefotaxime)
(P < 0.001) and total oral macrolides (Erythromycin, Azithro-
mycin and Clarithromycin) (P < 0.001). However, the individual
Table 2 Comparison of rates of pneumonia, hospitalization, disease severity and radiological findings between the two surveys per 10 000
children
2001 survey (n = 711) 2009 survey (n = 542) Change in IR*
Variables n (%) IR (95% CI) n (%) IR (95% CI) % (95% CI)
Pneumonia 711 (100) 14.4 (13.4 to 15.4) 542 (100) 11.8 (10.9 to 12.9) 17.7 (8 to 26)
Hospitalization 636 (89.5) 12.2 (11.3 to 13.2) 455 (84.0) 9.9 (9.0 to 10.9) 18.5 (8 to 28)
Pre-admission antibiotics 214 (30.0) 4.1 (3.6 to 4.7) 119 (22.0) 2.6 (2.2 to 3.1) 36.7 (20 to 49)
Disease severity
Mild/moderate 293 (41.2) 5.6 (5.0 to 6.3) 259 (47.8) 5.7 (5.0 to 6.4) −0.7 (–19 to 15)
Severe 418 (58.8) 8.0 (7.3 to 8.8) 283 (52.2) 6.2 (5.5 to 6.9) 22.9 (10 to 34)
Chest radiographic findings
Lobar 145 (20.4) 2.8 (2.3 to 3.3) 162 (29.9) 3.5 (3.0 to 4.1) –27.2 (–60 to −1)
Patchy 436 (61.3) 8.4 (7.6 to 9.2) 296 (54.6) 6.5 (5.7 to 7.2) 22.7 (20 to 33)
Perihilar 130 (18.3) 2.5 (2.1 to 2.9) 67 (12.4) 1.5 (1.1 to 1.9) 41.3 (20 to 57)
Other infiltrates – – 17 (3.1) 0.4 (0.2 to 0.6) –
Pleural effusion 65 (9.0) 1.2 (0.9 to 1.6) 52 (9.6) 1.1 (0.9 to 1.5) 8.9 (–33 to 38)
*Negative numbers denote an estimate of an increase in incidence.
CI, confidence interval; IR, incidence rate.
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use of Azithromycin or Clarithromycin remained the same, while
decreased for Erythromycin (P < 0.001).
Pre-guidelines, initial IV antibiotics were associated with severe
disease, lobar changes, pleural effusion or pyrexia (P < 0.05), but
not with oxygen saturation <93%. These associations were repli-
cated in post-guidelines with the initial use of IV antibiotics being
associated with severe disease (P = 0.0003), lobar changes
(P = 0.018) or pleural effusion (P = 0.041), but not with oxygen
saturation <93% or pyrexia. Comparing post- with pre-guidelines;
IV antibiotics were more likely to be given to those with lobar
changes (35% versus 25%) (OR = 0.6; 95% CI 0.45 to 0.85;
P = 0.004), but less likely to be given to children presenting with
low oxygen saturations (25% versus 34%) (OR = 0.6; 95% CI 0.45
to 0.89; P = 0.009). Mean (±SD) duration of hospitalization
decreased from the pre- to post-guidelines surveys (4.7 ± 7.16
versus 3.2 ± 3.02 days, P < 0.001). Those with severe disease,
lobar changes or pleural effusion had a longer stay (P < 0.001). All
children irrespective of their age group who received any IV anti-
biotics (alone or in combination with oral) had a longer average
duration of hospitalization than those who had only oral (4.1 ± 3.4
versus 2.0 ± 1.9 days, P < 0.001).
Discussion
This survey provides invaluable evaluation of the presentation and
management of PCAP seen in hospital over a year period focusing
on the investigations performed and antibiotic selection. Clinical
management of children with pneumonia has changed signifi-
cantly between 2002 and 2008. There have been a reduced number
of investigations performed, a change in the type of antibiotics, a
decrease in IV and a concomitant increase in oral antibiotics, and
a reduction in hospitalization rates and duration of stay. Reasons
for these changes are likely to be multifactorial such as the publi-
cation of the BTS management guidelines [6], an expanding
literature on oral/IV antibiotic use [22–25], and the routine intro-
duction of PCV7 in the UK in 2006. Findings from the present
survey are an important step in supporting the improvement in
adherence to the latest 2011 management guidelines [1].
Drivers of change are complex; some are likely to be literature
driven and others probably reflect the complex relationships
around perceived benefits and risks of IV cannulation,
venepuncture and differing usefulness of investigations. Adher-
ence to practice guidelines can be improved by regional studies
coupled with continuing education, feedback of audit data and
networking of junior and senior staff [26,27]. Our regional res-
piratory diseases research group and respiratory network consists
of staff from different disciplines, general and respiratory paedia-
tricians from the local hospitals around the region with regular
meetings, feedback and active research activities. Beside these
activities, participation in two surveys on the management of
PCAP helped raise awareness of management guidelines in all
centres. In contrast, a recent national BTS audit of a 3-year data
from 2009/2010 to 2011/2012 on the management of PCAP in the
UK showed an overuse of investigations to diagnose pneumonia
and under-prescription of oral antibiotics particularly Amoxicillin
[28].
It is interesting that fewer blood tests in terms of FBC and blood
cultures were taken, but just as many CRP samples were ordered.
The BTS guidelines including the recently updated version in 2011
[1] made no specific recommendations around FBC and discour-
aged use of acute phase reactants. Blood cultures were specifically
encouraged for those suspected of having a bacterial pneumonia in
2002 [6] but changed in 2011 [1] to be performed only in those
who presented with severe pneumonia. In the present survey, the
correlation between high CRP of >100 mg L−1 with pleural effu-
sion demonstrates the usefulness of CRP in differentiating
between uncomplicated and complicated pneumonia of bacterial
aetiology [29]. The reduction in collecting blood cultures perhaps
reflects the feeling that bacterial pneumonia is less likely given the
introduction of PCV7, which in the same population was associ-
ated with decreased disease incidence and rate of hospitalization
[20]. Although clinicians were not asked directly, the shift towards
less testing of respiratory secretions for either viruses or bacteria
could reflect the feeling that the results would not affect the deci-
sion on antibiotic use.
More positive changes are seen with antibiotic usage, encour-
aging for developing antimicrobial stewardship programmes.
These included a significant reduction in the use of antibiotics
prior to admission. This is in line with the observed substantial
decline since 1990s in the prescription of antibiotics in primary
care for lower respiratory tract infection in children [30]. This fall
in antibiotic prescriptions predate the published BTS management
guidelines of pneumonia in 2002 [6]. They reflect a continued fall
in the use of antibiotics despite a marginal increase in antibiotic
prescription during the period between 2003 and 2006, primarily
for non-specific upper respiratory tract infections, for which
national guidance aimed at primary care was introduced in 2008
[30,31]. IV antibiotics were used far less frequently than oral, with
a substantial increase in the use of Amoxicillin overall and orally,
at the expense of IV Cefuroxime and oral cephalosporins, which
decreased from one-fifth to 2%. In contrast, oral macrolides
remain frequently prescribed particularly to those aged under five,
similar to previous data [3], although not recommended as first line
treatment [6]. Evidence for the safety and efficacy of oral antibi-
otics even in severe pneumonia in children accumulated over the 6
years period between surveys, including a Cochrane review in
2006 [23] and the PIVOT trial in 2007 [24]. Recent pooled review
data showed that even severe pneumonia in young children can be
managed safely with oral antibiotics in primary care settings [25].
The selection of initial antibiotic route was influenced by
disease severity and lobar changes, possibly reflecting that these
criteria were considered markers of bacterial infection. The fact
that lobar changes were associated with high mean value of
inflammatory markers may support this. Other factors that could
have influenced the decision to give IV antibiotics, such as the
level of training of admitting medical staff or the knowledge of the
published guidelines, could not be ascertained with the data col-
lected. Substantial variation in the prescription of antibiotics for
children has been described, including both the proportion of
children exposed to antibiotics (38%–72%) and the duration of
treatment [32]. Also, considerable variability of antibiotic selec-
tion for the management of PCAP has been observed among pae-
diatric infectious disease consultants [33]. This variability in
antibiotic use highlights the need to implement and monitor effec-
tive antibiotic stewardship policies across and within hospitals to
reduce the over or under-use of them, thus reducing the risks
of development of antibiotic-resistant bacteria and treatment
failures [34].
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Conclusions
There has been a positive change in the management practices of
PCAP reflected by reduced number of overall investigations per-
formed and an increased preference for oral antibiotic use. This
was associated with decreased admission rates and shorter length
of hospital stay without increased complications. Adherence to
practice guidelines can be improved by regional projects coupled
with continuing education and feedback and networks of staff at
all grades. A cost-effectiveness analysis focusing on the impact of
reduced hospitalization, IV antibiotic use and pre-admission anti-
biotics would provide useful economic information on social cost.
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